Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 3/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1657246 | 1.00 | BUB1 (0.35) | BUB1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2598644 | 1.00 | BUB1 (0.35) | BUB1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23070591 | 0.88 | BUB1 (0.33) | BUB1 | |
| SCHEMBL20660395 | 0.83 | BUB1 (0.34) | BUB1 | |
| SCHEMBL6159950 | 0.83 | BUB1 (0.32) | BUB1 | |
| SCHEMBL31513965 | 0.83 | BUB1 (0.34) | BUB1 | |
| SCHEMBL3999602 | 0.81 | CRBN (0.40) | BUB1 | |
| SCHEMBL1852888 | 0.81 | PDE4A (0.37) | PDE4APDE4BPDE4CPDE4DTSHR | |
| SCHEMBL11090872 | 0.81 | PDE4A (0.37) | PDE4APDE4BPDE4CPDE4DTSHR | |
| SCHEMBL11090868 | 0.81 | PDE4A (0.37) | PDE4APDE4BPDE4CPDE4DTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055358-A | GPR65 small molecule regulator and preparation method and application thereof | 四川大学 | 2026-05-15 | — | — | CN | disclosed |
| WO-2024017178-A1 | SUBSTITUTED HYDANTOIN COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | AVITAR BIOSCIENCES, INC. (CN) | 2024-01-25 | — | — | WO | disclosed |
| EP-4308229-A1 | INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-117396469-A | Inhibitors of plasma kallikrein | 武田药品工业株式会社 | 2024-01-12 | — | — | CN | disclosed |
| WO-2022197763-A1 | INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| CN-112236161-A | Modulators of G protein-coupled receptors | 卡莫特治疗学股份有限公司 | 2021-01-15 | — | — | CN | disclosed |
| EP-3066094-B1 | PYRAZOLE FOR THE TREATMENT AUTOIMMUNE DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-01-08 | — | — | EP | disclosed |
| US-9890145-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-13 | — | — | US | disclosed |
| US-20160311811-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-27 | — | — | US | disclosed |
| EP-3066094-A1 | PYRAZOLE FOR THE TREATMENT AUTOIMMUNE DISORDERS | Takeda Pharmaceutical Company Limited (JP) | 2016-09-14 | — | — | EP | disclosed |
| WO-2010032200-A1 | AMIDE COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2010-03-25 | — | — | WO | disclosed |
| US-20090324569-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2009-12-31 | — | — | US | disclosed |
| US-20090324569-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2009-12-31 | — | — | US | disclosed |
| WO-2009067600-A2 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2009-05-28 | — | — | WO | disclosed |
| US-20080125429-A1 | Aryloxy-Substituted Benzimidazole Derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-05-29 | — | — | US | disclosed |
| EP-1810969-A1 | ARYLOXY-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-07-25 | — | — | EP | disclosed |
| EP-0474243-B1 | 1-Methylcarbapenem derivatives and process for preparation thereof | TANABE SEIYAKU CO (JP) | 1998-04-01 | — | — | EP | disclosed |
| US-5208348-A | Intermediates for thienamycin derivatives | TANABE SEIYAKU CO., LTD. (JP) | 1993-05-04 | — | — | US | disclosed |
| US-5153187-A | Microbiocides having stability against dehydropeptidase and high absorrbability by oral administration | TANABE SEIYAKU CO., LTD. (JP) | 1992-10-06 | — | — | US | disclosed |
| EP-0474243-A1 | 1-Methylcarbapenem derivatives and process for preparation thereof | TANABE SEIYAKU CO., LTD. (JP) | 1992-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311811-A1 | HETEROCYCLIC COMPOUND | IRAK4, IRAK1, IRAK2 | BUB1 2816/4885PDE4A 704/4885PDE4B 692/4885 |
| US-20080125429-A1 | Aryloxy-Substituted Benzimidazole Derivatives | GCK, GCKR, SLC5A1 | BUB1 3363/4885PDE4A 2848/4885PDE4B 2552/4885 |
| US-20090324569-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | PDE4A, PDE4B, PDE3B | BUB1 4642/4885PDE4A 1/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.